HealthLeaders-InterStudy, a leading provider of managed care industry intelligence, reports that while PPOs certainly continue to show membership gains in Florida, employers are again looking to HMOs for cost control. According to the latest issue of Florida Health Plan Analysis, six new HMOs were licensed in the state last year, most of them for Medicare and Medicaid.

"Members like the bells and whistles offered as part of PPO plans," said Jan Shuxteau, HealthLeaders-InterStudy analyst. "But employers have found that many employees don't end up taking advantage of the extra flexibility that drives up the cost of these plans. I wouldn't be surprised to see price- conscious employers taking another look at the HMO model."

  Other health plan news in Florida:   * Some 25 organizations and provider groups have submitted letters of     intent to become approved coordinated care organizations under     Florida's Medicaid reform program.   * Seventy percent of Florida Medicare eligibles are enrolled in the new     Part D drug program.   * CIGNA is introducing a "custom benefit builder" for some of its     membership, allowing them to choose such things as co-payments and     deductibles, and see the resulting required monthly payment.    About Health Plan Analysis 

Health Plan Analysis identifies key health plan trends, allowing healthcare businesses to create comprehensive strategic plans and sales strategies at state and local levels.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a company of Decision Resources, Inc. (http://www.decisionresources.com/), is the authoritative source for managed care data and analysis. For more information, please visit http://www.healthleaders-interstudy.com/.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Alex Jablokow    Decision Resources    781-296-2562    ajablokow@dresources.com 

SOURCE: HealthLeaders-InterStudy

CONTACT: Alex Jablokow of Decision Resources, +1-781-296-2562,
ajablokow@dresources.com

FDA's Likely Approval to Relaunch Tysabri, Despite Rare Fatal Side Effects, Demonstrates Significant Need for Effective Treatments Against Multiple Sclerosis

View Now